Maxxon

Maxion Therapeutics is a UK-based biotechnology company focused on developing innovative antibody-based therapeutics for ion channels and G protein-coupled receptors (GPCRs). The company utilizes its proprietary KnotBody platform, which engineers cysteine-rich miniproteins (knottins) into antibody loops to create highly specific and potent modulators of traditionally difficult-to-drug targets. Maxion's current pipeline is primarily focused on addressing significant unmet needs in chronic pain and autoimmune disorders. By combining the specificity of antibodies with the functional diversity of knottins, the company aims to overcome the limitations of small molecule and traditional antibody approaches in these therapeutic areas.